Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

"You’d think companies would want their products’ names to be memorable, catchy and descriptive: Windex, Duracell, KitchenAid ...

Across the three-year clinical trial data for PsA and axSpA, BIMZELX was generally well-tolerated and no new safety signals were observed.2-4 The most common treatment-emergent adverse events ...

Belgian drugmaker UCB (Euronext: UCB) today announced new three-year data from Phase III trials, and their open-label ...

BIMZELX ® is the first and only approved medicine designed to selectively inhibit interleukin 17A (IL-17A) in addition to interleukin 17F (IL-17F) ...

BIMZELX, a dual inhibitor of IL-17A and IL-17F, 1 demonstrated sustained control of inflammation and deep efficacy in patients living with PsA and axSpA, 2-5 chronic inflammatory diseases with ...

(RTTNews) - UCB (UCB) announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...